

## Disclosures

### Personal Commercial (17)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Alnylam	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Amgen	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Amgen	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Arena	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bristol Myers Squibb	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Cardionomic	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cytokinetics	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
EBR Systems	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
LivaNova	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novartis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Roche Diagnostics	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Rocket	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
SC Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

### Personal Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Heart Association	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
NHLBI	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

## Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

---

### Certified Education Attestation | Signed on 7/19/2019

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### Confidentiality, Disclosure and Assignment Agreement | Signed on 7/19/2019

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### Embargo | Signed on 7/19/2019

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### On-Going Obligation Agreement | Signed on 7/19/2019

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.